A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii

References

• Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016;47(4):317–23. doi:10.1016/j.ijantimicag.2016.01.015
   PubMed Web of Science ®Google Scholar
• Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951–7. doi:10.1016/j.cmi.2019.03.014
   PubMed Web of Science ®Google Scholar
• Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2019;75(2):271–82. doi:10.1093/jac/dkz401
   Web of Science ®Google Scholar
• Karakonstantis S, Kritsotakis E, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii Co-resistant to carbapenems, aminoglycosides, colistin and tigecycline. An approach based on the mechanisms of resistance to carbapenems. Preprints 2020. doi:10.20944/preprints202006.0173.v1
   Google Scholar
• Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67(7):1607–15. doi:10.1093/jac/dks084
   PubMed Web of Science ®Google Scholar
• Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp; systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents. 2020. doi:10.1016/j.ijantimicag.2020.106065
   PubMed Web of Science ®Google Scholar
• Da Silva GJ, Domingues S. Interplay between colistin resistance, virulence and fitness in Acinetobacter baumannii. Antibiotics (Basel). 2017;6(4):28. doi:10.3390/antibiotics6040028
   Web of Science ®Google Scholar
• Beceiro A, Moreno A, Fernández N, Vallejo JA, Aranda J, Adler B, Harper M, Boyce JD, Bou G. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58(1):518–26. doi:10.1128/aac.01597-13
   PubMed Web of Science ®Google Scholar
• Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy. 2007;27(8):1198–201. doi:10.1592/phco.27.8.1198
   PubMed Web of Science ®Google Scholar
• Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother. 2007;59(5):1001–4. doi:10.1093/jac/dkm058
   PubMed Web of Science ®Google Scholar
• Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008;46(4):567–70. doi:10.1086/526775
   PubMed Web of Science ®Google Scholar
• David MD, Gill MJ. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother. 2008;61(4):962–4. doi:10.1093/jac/dkn009
   PubMed Web of Science ®Google Scholar
• Higgins PG, Schneiders T, Hamprecht A, Seifert H. In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. Antimicrob Agents Chemother. 2010;54(12):5021–7. doi:10.1128/aac.00598-10
   PubMed Web of Science ®Google Scholar
• Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, Quinn J, Lolans K, Livermore DM, Woodford N, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010;65(8):1589–93. doi:10.1093/jac/dkq218
   PubMed Web of Science ®Google Scholar
• Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF, Underwood A, Gaulton T, Thomas CP, Doumith M, et al. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother. 2011;66(7):1499–503. doi:10.1093/jac/dkr168
   PubMed Web of Science ®Google Scholar
• Hornsey M, Wareham DW. Effects of in vivo emergent tigecycline resistance on the pathogenic potential of Acinetobacter baumannii. Sci Rep. 2018;8(1):4234. doi:10.1038/s41598-018-22549-6
   PubMedGoogle Scholar
• Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55(7):3370–9. doi:10.1128/aac.00079-11
   PubMed Web of Science ®Google Scholar
• López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis. 2011;204(7):1147–8. doi:10.1093/infdis/jir476
   PubMed Web of Science ®Google Scholar
• Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, Dominguez-Herrera J, Fernandez-Cuenca F, Pachon J. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother. 2013;57:4587–9. doi:10.1128/aac.00543-13
   PubMed Web of Science ®Google Scholar
• Rolain JM, Roch A, Castanier M, Papazian L, Raoult D. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis. 2011;204(7):1146–7. doi:10.1093/infdis/jir475
   PubMed Web of Science ®Google Scholar
• Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France. Antimicrob Agents Chemother. 2013;57(1):592–6. doi:10.1128/aac.01314-12
   PubMed Web of Science ®Google Scholar
• Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain J-M, Raoult D, Brunel J-M, Papazian L, Brégeon F, et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother. 2013;57(10):5120–1. doi:10.1128/AAC.00700-13
   PubMed Web of Science ®Google Scholar
• Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, Toyoda Y, Pilewski JM, Crespo M, Pasculle AW, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis. 2011;70(2):246–52.
   PubMed Web of Science ®Google Scholar
• Lesho E, Yoon E-J, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208(7):1142–51. doi:10.1093/infdis/jit293
   PubMed Web of Science ®Google Scholar
• Jones CL, Singh SS, Alamneh Y, Casella LG, Ernst RK, Lesho EP, Waterman PE, Zurawski DV. In vivo fitness adaptations of colistin-resistant Acinetobacter baumannii isolates to oxidative stress. Antimicrob Agents Chemother. 2017;61(3):e00598–16. doi:10.1128/AAC.00598-16
   PubMed Web of Science ®Google Scholar
• Snitkin ES, Zelazny AM, Gupta J, Palmore TN, Murray PR, Segre JA, NISC Comparative Sequencing Program. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res. 2013;23(7):1155–62. doi:10.1101/gr.154328.112
   PubMed Web of Science ®Google Scholar
• Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis. 2014;79(3):362–6. doi:10.1016/j.diagmicrobio.2014.03.027
   PubMed Web of Science ®Google Scholar
• Pournaras S, Poulou A, Dafopoulou K, Chabane YN, Kristo I, Makris D, Hardouin J, Cosette P, Tsakris A, Dé E, et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58(2):828–32. doi:10.1128/aac.01439-13
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2015;82(3):222–6. doi:10.1016/j.diagmicrobio.2015.03.013
   PubMed Web of Science ®Google Scholar
• Lim TP, Ong RT-H, Hon P-Y, Hawkey J, Holt KE, Koh TH, Leong ML-N, Teo JQ-M, Tan TY, Ng MM-L, et al. Multiple genetic mutations associated with polymyxin resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(12):7899–902. doi:10.1128/aac.01884-15
   PubMed Web of Science ®Google Scholar
• Liu L, Cui Y, Zheng B, Jiang S, Yu W, Shen P, Ji J, Li L, Qin N, Xiao Y, et al. Analysis of tigecycline resistance development in clinical Acinetobacter baumannii isolates through a combined genomic and transcriptomic approach. Sci Rep. 2016;6:26930. doi:10.1038/srep26930
   PubMed Web of Science ®Google Scholar
• Wright MS, Iovleva A, Jacobs MR, Bonomo RA, Adams MD. Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Med. 2016;8(1):26. doi:10.1186/s13073-016-0279-y
   PubMedGoogle Scholar
• Choi HJ, Kil MC, Choi J-Y, Kim SJ, Park K-S, Kim Y-J, Ko KS. Characterisation of successive Acinetobacter baumannii isolates from a deceased haemophagocytic lymphohistiocytosis patient. Int J Antimicrob Agents. 2017;49(1):102–6. doi:10.1016/j.ijantimicag.2016.09.024
   PubMed Web of Science ®Google Scholar
• Dahdouh E, Gómez-Gil R, Sanz S, González-Zorn B, Daoud Z, Mingorance J, Suárez M. A novel mutation in pmrB mediates colistin resistance during therapy of Acinetobacter baumannii. Int J Antimicrob Agents. 2017;49(6):727–33. doi:10.1016/j.ijantimicag.2017.01.031
   PubMed Web of Science ®Google Scholar
• Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A, Soo Shin B, Kaye KS, Bulitta JB, Nation RL, et al. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother. 2017;72(5):1415–20. doi:10.1093/jac/dkx002
   PubMed Web of Science ®Google Scholar
• Savari M, Ekrami A, Shoja S, Bahador A. Acquisition of Tn6018-3' CS regions increases colistin MICs against Acinetobacter baumannii isolates harboring new variants of AbaRs. Folia Microbiol (Praha)). 2017;62(5):373–9. doi:10.1007/s12223-017-0507-x
   PubMed Web of Science ®Google Scholar
• Cafiso V, Stracquadanio S, Lo Verde F, Gabriele G, Mezzatesta ML, Caio C, Pigola G, Ferro A, Stefani S. Colistin resistant A. baumannii: genomic and transcriptomic traits acquired under colistin therapy. Front Microbiol. 2018;9:3195doi:10.3389/fmicb.2018.03195
   PubMed Web of Science ®Google Scholar
• Deveson Lucas D, Crane B, Wright A, Han M-L, Moffatt J, Bulach D, Gladman SL, Powell D, Aranda J, Seemann T, et al. Emergence of high-level colistin resistance in an Acinetobacter baumannii clinical isolate mediated by inactivation of the global regulator H-NS. Antimicrob Agents Chemother. 2018;62(7):e02442-17. doi:10.1128/aac.02442-17
   PubMed Web of Science ®Google Scholar
• Farshadzadeh Z, Taheri B, Rahimi S, Shoja S, Pourhajibagher M, Haghighi MA, Bahador A. Growth rate and biofilm formation ability of clinical and laboratory-evolved colistin-resistant strains of Acinetobacter baumannii. Front Microbiol. 2018;9:153doi:10.3389/fmicb.2018.00153
   PubMed Web of Science ®Google Scholar
• Gerson S, Nowak J, Zander E, Ertel J, Wen Y, Krut O, Seifert H, Higgins PG. Diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with tigecycline resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2018;73(6):1501–8. doi:10.1093/jac/dky083
   PubMed Web of Science ®Google Scholar
• Jaidane N, Naas T, Mansour W, Radhia BB, Jerbi S, Boujaafar N, Bouallegue O, Bonnin RA. Genomic analysis of in vivo acquired resistance to colistin and rifampicin in Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51(2):266–9. doi:10.1016/j.ijantimicag.2017.10.016
   PubMed Web of Science ®Google Scholar
• Mustapha MM, Li B, Pacey MP, Mettus RT, McElheny CL, Marshall CW, Ernst RK, Cooper VS, Doi Y. Phylogenomics of colistin-susceptible and resistant XDR Acinetobacter baumannii. J Antimicrob Chemother. 2018;73(11):2952–9. doi:10.1093/jac/dky290
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295–303. doi:10.1093/cid/civ048
   PubMed Web of Science ®Google Scholar
• Saun TJ, Rogers AD, Leis JA, Cartotto R. The use of intravenous and inhaled colistin therapy during a burn center outbreak of multidrug-resistant Acinetobacter baumannii. J Burn Care Res. 2018;39(6):1029–36. doi:10.1097/bcr.0000000000000626
   PubMed Web of Science ®Google Scholar
• Gerson S, Betts JW, Lucaßen K, Nodari CS, Wille J, Josten M, Göttig S, Nowak J, Stefanik D, Roca I, et al. Investigation of Novel pmrB and eptA mutations in isogenic Acinetobacter baumannii isolates associated with colistin resistance and increased virulence in vivo. Antimicrob Agents Chemother. 2019;63(3):e01586-18. doi:10.1128/aac.01586-18
   PubMed Web of Science ®Google Scholar
• Cheng J, Kesavan DK, Vasudevan A, Cai W, Wang H, Su Z, et al. Genome and transcriptome analysis of A. baumannii's “Transient” increase in drug resistance under tigecycline pressure. J Glob Antimicrob Resist. 2020;22:219–25. doi:10.1016/j.jgar.2020.02.003
   PubMed Web of Science ®Google Scholar
• Marano V, Marascio N, Pavia G, Lamberti AG, Quirino A, Musarella R, Casalinuovo F, Mazzitelli M, Trecarichi EM, Torti C, et al. Identification of pmrB mutations as putative mechanism for colistin resistance in A. baumannii strains isolated after in vivo colistin exposure. Microb Pathog. 2020;142:104058. doi:10.1016/j.micpath.2020.104058
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi:10.1016/s1473-3099(18)30099-9
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58. doi:10.1093/cid/cit253
   PubMed Web of Science ®Google Scholar
• Jean S-S, Hsieh T-C, Lee W-S, Hsueh P-R, Hsu C-W, Lam C. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: is there any benefit of adding tigecycline to aerosolized colistimethate sodium? Medicine. 2018;97(39):e12278. doi:10.1097/MD.0000000000012278
   PubMed Web of Science ®Google Scholar
• Dickstein Y, Lellouche J, Dalak Amar MB, Schwartz D, Nutman A, Daitch V, et al. Treatment outcomes of colistin and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis. 2018;69(5):769–76. doi:10.1093/cid/ciy988
   Web of Science ®Google Scholar
• Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51(4):535–47. doi:10.1016/j.ijantimicag.2017.12.020
   PubMed Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29–39. doi:10.1093/jac/dkw377
   PubMed Web of Science ®Google Scholar
• Cheng IL, Chen YH, Lai CC, Tang HJ. Intravenous colistin monotherapy versus combination therapy against carbapenem-resistant gram-negative bacteria infections: meta-analysis of randomized controlled trials. J Clin Med. 2018;7(8):208. doi:10.3390/jcm7080208
   Web of Science ®Google Scholar
• Wang J, Niu H, Wang R, Cai Y. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: a systematic review and meta-analysis. Int J Antimicrob Agents. 2019;53(4):383–400. doi:10.1016/j.ijantimicag.2018.10.020
   PubMed Web of Science ®Google Scholar
• Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, et al. Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;S1198-743X(20)30181-6. doi:10.1016/j.cmi.2020.03.035
   Web of Science ®Google Scholar
• Karakonstantis S. Re: ‘Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes’ by Nutman et al. Clin Microbiol Infect. 2020. doi:10.1016/j.cmi.2020.04.043
   Web of Science ®Google Scholar
• Wong FH, Cai Y, Leck H, Lim TP, Teo JQ, Lee W, et al. Determining the development of persisters in extensively drug-resistant Acinetobacter baumannii upon exposure to polymyxin B-based antibiotic combinations using flow cytometry. Antimicrob Agents Chemother. 2020;64(3):e01712–19. doi:10.1128/aac.01712-19
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. AAC. 2006;50(9):2946–50. doi:10.1128/aac.00103-06
   Google Scholar
• Cai X, Yang Z, Dai J, Chen K, Zhang L, Ni W, Wei C, Cui J. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Int J Antimicrob Agents. 2017;49(5):609–16. doi:10.1016/j.ijantimicag.2017.01.007
   PubMed Web of Science ®Google Scholar
• Assimakopoulos SF, Karamouzos V, Lefkaditi A, Sklavou C, Kolonitsiou F, Christofidou M, Fligou F, Gogos C, Marangos M. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study. Infez Med. 2019;27(1):11–6.
   PubMedGoogle Scholar
• Bae S, Kim M-C, Park S-J, Kim HS, Sung H, Kim M-N, Kim S-H, Lee S-O, Choi S-H, Woo JH, et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(11):6774–9. doi:10.1128/AAC.00839-16
   PubMed Web of Science ®Google Scholar
• Poulakou G, Renieris G, Sabrakos L, Zarkotou O, Themeli-Digalaki K, Perivolioti E, et al. Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin. Int J Antimicrob Agents. 2019;53(2):190–94. doi:10.1016/j.ijantimicag.2018.10.024
   PubMed Web of Science ®Google Scholar